Efficacy of dupilumab in moderate and severe atopic dermatitis
-
- Stephan Weidinger
- Department of Dermatology and Allergy University Hospital Schleswig‐Holstein Campus Kiel Kiel Germany
-
- Eric L. Simpson
- Department of Dermatology Oregon Health and Science University Portland Oregon USA
-
- Jonathan I. Silverberg
- School of Medicine and Health Sciences George Washington University Washington District of Columbia USA
-
- Jochen Schmitt
- Centre for Evidence‐Based Healthcare, Medizinische Fakultät Carl Gustav Carus TU Dresden Dresden Germany
-
- Yael A. Leshem
- Division of Dermatology, Rabin Medical Center Beilinson Hospital Petach Tikva Israel
-
- Norito Katoh
- Department of Dermatology, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
-
- Zhen Chen
- Regeneron Pharmaceuticals Inc. Tarrytown New York USA
-
- Haixin Zhang
- Regeneron Pharmaceuticals Inc. Tarrytown New York USA
-
- Brad Shumel
- Regeneron Pharmaceuticals Inc. Tarrytown New York USA
-
- Ashish Bansal
- Regeneron Pharmaceuticals Inc. Tarrytown New York USA
-
- Jingdong Chao
- Regeneron Pharmaceuticals Inc. Tarrytown New York USA
-
- Yufang Lu
- Regeneron Pharmaceuticals Inc. Tarrytown New York USA
-
- Ana B. Rossi
- Sanofi Cambridge Massachusetts USA
-
- Alvina Abramova
- Regeneron Pharmaceuticals Inc. Tarrytown New York USA
抄録
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Treatment responses may differ between patients with severe versus moderate atopic dermatitis (AD).</jats:p></jats:sec><jats:sec><jats:title>Objectives</jats:title><jats:p>To assess dupilumab response by baseline AD severity in adolescent and adult patients with moderate‐to‐severe AD.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We assessed dupilumab response by baseline AD severity in 1719 patients aged ≥12 years with moderate‐to‐severe AD from five randomized, double‐blind, placebo‐controlled trials. Patients received subcutaneous placebo or dupilumab as monotherapy (300 mg [adults, adolescents] or 200 mg [adolescents] every 2 weeks; 16 weeks), or with concomitant topical corticosteroids (TCS) (adults; 16/52 weeks). Patients were stratified by baseline Investigator's Global Assessment (IGA) score (3 [moderate]/4 [severe]).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Dupilumab‐treated patients with moderate AD had numerically higher absolute proportions of patients achieving IGA 0/1 (clear/almost clear) than those with severe AD; risk differences (dupilumab vs. placebo) were 18.9–35.5 for moderate AD and 16.4–34.2 for severe AD. For all other endpoints assessed, no meaningful differences or consistent response patterns between moderate and severe subgroups were observed.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Dupilumab with or without TCS demonstrated similar efficacy in patients with moderate or severe AD.</jats:p></jats:sec>
収録刊行物
-
- JEADV Clinical Practice
-
JEADV Clinical Practice 2 (2), 247-260, 2023-03-02
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360017279858296832
-
- DOI
- 10.1002/jvc2.100
-
- ISSN
- 27686566
-
- データソース種別
-
- Crossref
- KAKEN